Zymeworks: Transitioning Into A Royalty-Driven Biopharma Platform Post Ziihera Approval

seekingalpha.com · 2026-08-27

Zymeworks' zanidatamab’s first-line HER2+ gastroesophageal cancer approval expands the eligible patient population. Find out why ZYME stock is a buy.